| Product NDC: | 49288-0643 |
| Proprietary Name: | Jack Pine Pollen |
| Non Proprietary Name: | Jack Pine Pollen |
| Active Ingredient(s): | .05 g/mL & nbsp; Jack Pine Pollen |
| Administration Route(s): | INTRADERMAL; SUBCUTANEOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 49288-0643 |
| Labeler Name: | Antigen Laboratories, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA102223 |
| Marketing Category: | BLA |
| Start Marketing Date: | 19740323 |
| Package NDC: | 49288-0643-2 |
| Package Description: | 5 mL in 1 VIAL, MULTI-DOSE (49288-0643-2) |
| NDC Code | 49288-0643-2 |
| Proprietary Name | Jack Pine Pollen |
| Package Description | 5 mL in 1 VIAL, MULTI-DOSE (49288-0643-2) |
| Product NDC | 49288-0643 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Jack Pine Pollen |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRADERMAL; SUBCUTANEOUS |
| Start Marketing Date | 19740323 |
| Marketing Category Name | BLA |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | PINUS BANKSIANA POLLEN |
| Strength Number | .05 |
| Strength Unit | g/mL |
| Pharmaceutical Classes | Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient] |